Elexacaftor-tezacaftor-ivacaftor in patients with cystic fibrosis ineligible for clinical trials: a 24-week observational study

• 主要な著者: Libor Fila (著者), Alzbeta Grandcourtova (著者), Alena Bilkova (著者), Pavel Drevinek (著者)
• フォーマット: 図書
• 出版事項: Frontiers Media S.A., 2023-06-01T00:00:00Z.
• 主題: article
• オンライン･アクセス: Connect to this object online.

Introduction: Seminal clinical trials with the triple combination of elexacaftor-tezacaftor-ivacaftor (ETI) demonstrated clinical efficacy in people with cystic fibrosis (pwCF) who carry at least one F508del mutation. However, due to exclusion criteria of these clinical trials, the effect of ETI was...